As per our report, the global autoinjectors market size was worth USD 2.72 billion in 2019. This market is estimated to be growing at a CAGR of 16.85% and will reach USD 5.93 billion by 2024. Patients are encouraged to use chronic disease with this technology. Multi-national companies are focusing on developing markets such as the Asia-Pacific region due to the availability of well-developed manufacturing infrastructure and low-cost jobs.
Autoinjectors are used to deliver a single dose of a drug, mainly life-saving drugs. These autoinjectors are spring-loaded syringes which are mostly designed for safe and secure application of the drugs. The auto-injector delivery method that is driven market and made a paradigm shift. The self-injection devices are primarily used for delivering human growth hormones, and technologically advanced autoinjectors recently replace insulin.
MARKET DRIVERS
Rising prevalence of anaphylaxis attacks is majorly driving the global autoinjectors market growth.
An anaphylaxis attack can be life-threatening. Growing incidence of these attacks is directly influencing the global autoinjectors market. The prevalence of these attacks is high in America compared to the countries around the world. The rising patient counts of diabetes, Rheumatoid arthritis patients and cancer are some of the other vital factors which are responsible for the fuelling the growth of the global autoinjectors market. Also, the approvals and funding given by the government are anticipating the growth of global autoinjectors market.
Additionally, factors such as technological advancement and innovation in drug delivery systems, increased adoption of autoinjectors are expected to drive market growth. Soaring prevalence of diabetes and cancer, simplification of self-medication and improved patient adherence, many advantages such as security, comfort and precision are favouring the market growth. Favourable government policies and high investments are further expected to push the global autoinjectors market growth.
MARKET RESTRAINTS
High prices, lack patient awareness towards self-medication, injuries associated with autoinjectors and are hindering the global market growth to some extent. Moreover, stringent regulations, lack awareness of self-injectors in the patients is less, and the infections caused by the needle- stick and injuries are further restraining the global autoinjectors market growth.
REPORT COVERAGE
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2018 to 2024 |
|
Base Year |
2018 |
|
Forecast Period |
2019 to 2024 |
|
Segments Covered |
By Product, Manufacturing Design, Usability, Technology, Application, Distribution Channels and Region. |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities. |
|
Regions Covered |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa. |
This market research report on the global autoinjectors market has been segmented and sub-segmented based on the product, manufacturing design, usability, technology, application, distribution channels and region.
Autoinjectors Market - By Product
Based on the product, the largest segment of prefilled autoinjectors is expected to remain dominant throughout the forecast period. They come with standard prefilled drug barrels and are simple to use. The most significant advantage provided by prefilled syringes is the elimination of dose error.
Autoinjectors Market – By Usability
Based on usability, Because of its ease of use, convenience, and patient preference, the disposable autoinjectors segment accounted for the largest share in 2018. Variables such as increased patient awareness and patient inclination toward using self-administration, increased demand for autoinjectors due to increased incidence of anaphylaxis, as well as other emergency conditions, combined with simple-to-use autoinjectors are significant forces driving growth for this segment. The segment of Reusable Autoinjectors is projected to be the fastest-growing segment during the forecast period. Reusable autoinjectors are provided in two types, like autoinjectors that are prefilled and empty.
Autoinjectors Market – By Manufacturing Design
Based on the manufacturing design, the standardized auto-injectors are estimated to hold the largest share over the forecast period. It is due to the factors like growing occurrences of cancer and diabetic cases, the launch of reimbursement policies by government and making betterment changes in increasing concentration on research and development. However, the customized auto-injectors estimated to showcase the highest growth rate during the forecast period.
Autoinjectors Market – By Technology
Based on technology, the automated auto-injectors segment led the market in 2019. Increasing obtainment of these automated auto-injectors among the patient population, particularly during emergencies and raising awareness through campaigns are significantly pushing the growth for this market. Growing regulatory approvals and increasing usage of biologics for drug delivery are some other factors propelling growth.
Autoinjectors Market – By Application
Based on application, the segment of anaphylaxis was accounted for the highest share in 2018. This significant proportion can be attributed to increased incidence of anaphylactic reactions due to stings of food, medicines, latex, and insects.
The segment of Rheumatoid Arthritis is anticipated to hold a substantial share in the market throughout the forecast period. Most of the patients with rheumatoid arthritis using an autoinjector for treatment were found to be confident with the system. They had even better outcomes than those who obtained injections from someone else.
Autoinjectors Market – By Distribution Channels
Regional Analysis
Regionally, North America has the largest market with the United States has a significant contributor to the revenue due to the rising cases of anaphylaxis, an increase in disposable income and growth in the pharmaceutical industry. In the United States, rising incidents of Anaphylaxis and Rheumatoid arthritis is propelling the demand of the market. As per the America Academy of Paediatrics, about 7.6% amongst 5.6 million children in the United States had food allergies.
The Asia Pacific is anticipated to have a significant growth rate in the forecast period. Due to the growing presence of diabetic patient count and increasing population. In this region, countries are accepting and developing new products boosting the market growth. Similarly, India, China and Japan are expected to contribute pointedly to the market growth.
Europe has occupied the second-largest share in the global autoinjectors market. The European market is predicted to grow at a CAGR of 16.32% during the forecast period. Standard increase in the rate of chronic diseases and also increasing funds and investments in research and development activities by the key players, particularly by the private organizations in this region are majorly fueling the market growth. In Europe, Germany Autoinjectors market is leading with the most significant shares of the European autoinjectors market.
The Latin American market is estimated to display a CAGR value of 16% throughout the forecast period. Brazil is one of the leading nations followed by Mexico, Argentina and Columbia. The growth is allocated due to favourable government policies and also huge funds by private organizations. The growth is attributed due to growing investments contributed by the key players, increasing awareness associated with the utilization of auto-injectors, and also the support from the government.
The Middle East & Africa region is expected to have sluggish growth over the forecast period. The growth of the market is credited due to the deficient healthcare infrastructure, particularly in the African region.
TOP COMPANIES IN THE MARKET
Key market participants in the global autoinjectors market profiled in this report are Mylan N.V., Pfizer, Inc., Bayer AG, Becton, Dickinson and Company, Novartis AG, Biogen Idec, Inc., Janssen Global Services, LLC, Sanofi, Unilife Corporation and Eli Lilly and Company.
RECENT MARKET DEVELOPMENTS
On November 27, 2018, Teva’s pharmaceuticals made a public statement in which they announced that they are releasing the generic version of EpiPen auto-injector 0.3mg in the U.S. which was approved by the U.S. FDA. It is used for patients who are suffering from the danger of allergic emergencies.
On August 06, 2018, Pfizer decided to make a contract with Antares set up to release auto-injector for an unnamed drug.
On May 31, 2017, Bayer won the FDA approval for Beta Connect auto-injector. This Beta Connect auto-injector manages Betaseron for fragile patients. It allows the patient to connect with the new software my beta app to share their data related to health with the healthcare team.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Product
5.1.1 Introduction
5.1.2 Fillable Autoinjectors
5.1.3 Prefilled Autoinjectors
5.1.4 Y-o-Y Growth Analysis, By Product
5.1.5 Market Attractiveness Analysis, By Product
5.1.6 Market Share Analysis, By Product
5.2 Usability
5.2.1 Introduction
5.2.2 Disposable Autoinjectors
5.2.3 Reusable Autoinjectors
5.2.4 Y-o-Y Growth Analysis, By Usability
5.2.5 Market Attractiveness Analysis, By Usability
5.2.6 Market Share Analysis, By Usability
5.3 Manufacturing Design
5.3.1 Introduction
5.3.2 Standardized Autoinjectors
5.3.3 Customized Autoinjectors
5.3.4 Y-o-Y Growth Analysis, By Manufacturing Design
5.3.5 Market Attractiveness Analysis, By Manufacturing Design
5.3.6 Market Share Analysis, By Manufacturing Design
5.4 Technology
5.4.1 Introduction
5.4.2 Automated Autoinjectors
5.4.3 Manual Autoinjectors
5.4.4 Y-o-Y Growth Analysis, By Technology
5.4.5 Market Attractiveness Analysis, By Technology
5.4.6 Market Share Analysis, By Technology
5.5 Application
5.5.1 Introduction
5.5.2 Anaphylaxis
5.5.3 Multiple Sclerosis
5.5.4 Rheumatoid Arthritis
5.5.5 Y-o-Y Growth Analysis, By Application
5.5.6 Market Attractiveness Analysis, By Application
5.5.7 Market Share Analysis, By Application
5.6 Distribution Channels
5.6.1 Introduction
5.6.2 Hospitals
5.6.3 Retail
5.6.4 Online Pharmacies
5.6.5 Others
5.6.6 Y-o-Y Growth Analysis, By Distribution Channels
5.6.7 Market Attractiveness Analysis, By Distribution Channels
5.6.8 Market Share Analysis, By Distribution Channels
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Product
6.1.3.3 By Usability
6.1.3.4 By Manufacturing Design
6.1.3.5 By Technology
6.1.3.6 By Application
6.1.3.7 By Distribution Channels
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Product
6.1.4.3 By Usability
6.1.4.4 By Manufacturing Design
6.1.4.5 By Technology
6.1.4.6 By Application
6.1.4.7 By Distribution Channels
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Product
6.1.5.3 By Usability
6.1.5.4 By Manufacturing Design
6.1.5.5 By Technology
6.1.5.6 By Application
6.1.5.7 By Distribution Channels
6.2 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.3 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.4 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 Australia
6.3.6 South Korea
6.5 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Argentina
6.4.4 Mexico
6.4.5 Rest of Latin America
6.6 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Mylan N.V.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer, Inc.,
8.3 Bayer AG
8.4 Becton, Dickinson and Company
8.5 Novartis AG
8.6 Biogen Idec, Inc.,
8.7 Janssen Global Services
8.8 Sanofi
8.9 Eli Lilly and Company
8.10 Unilife Corporation
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
Aug 2019
Download Sample
